Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs TeleCareSpot

Coivas
Graded #194

Lower grade

vs+1.5
TeleCareSpot
Graded #160

Higher grade

The verdict

TeleCareSpot takes it — 67.7/100 to 66.2/100, but only just.

TeleCareSpot grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TeleCareSpot is a telehealth weight-loss platform offering doctor-prescribed compounded GLP-1s with flat, all-inclusive monthly pricing: compounded semaglutide at $299/month and tirzepatide at $399/month… Coivas is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoivas +27
70
43
Dose & formulationTeleCareSpot +19
64
83
Clinical oversightCoivas +1
84
83
Labs & monitoringCoivas +2
54
52
FulfillmentTeleCareSpot +14
78
92
Contract termsTeleCareSpot +41
20
61
Coivas · left barTeleCareSpot · right bar

The numbers

MetricCoivasTeleCareSpot
WeighScore66.2/10067.7/100
GradeCC
Scorecard rank#194#160
Semaglutide$149/mo (quarterly plan, compounded)$299/mo (all doses, plus a separate fee, compounded)
Tirzepatide$229/mo (quarterly plan, compounded)$399/mo
CoverageCoverage not published48 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Coivas

Graded #194 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
TeleCareSpot

Graded #160 · C

Strengths

  • Flat, all-inclusive monthly pricing with no hidden fees — compounded semaglutide $299/month and tirzepatide $399/month, all doses included
  • Verifiable LegitScript certification (seal ID 45936855) plus HIPAA compliance and licensed US physicians
  • Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
  • DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
  • Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Not available in Alaska, Mississippi, or New Jersey
  • The compounding pharmacy partner is not named
  • A separate weight-loss consultation fee applies (credited toward your medication package if approved)
  • Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard